Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.

Patients with Marfan syndrome (MFS), a multisystem disorder caused by mutations in the gene encoding the extracellular matrix (ECM) protein fibrillin 1, are unusually vulnerable to stress-induced cardiac dysfunction. The prevailing view is that MFS-associated cardiac dysfunction is the result of aortic and/or valvular disease. Here, we determined that dilated cardiomyopathy (DCM) in fibrillin 1-deficient mice is a primary manifestation resulting from ECM-induced abnormal mechanosignaling by cardiomyocytes. MFS mice displayed spontaneous emergence of an enlarged and dysfunctional heart, altered physical properties of myocardial tissue, and biochemical evidence of chronic mechanical stress, including increased angiotensin II type I receptor (AT1R) signaling and abated focal adhesion kinase (FAK) activity. Partial fibrillin 1 gene inactivation in cardiomyocytes was sufficient to precipitate DCM in otherwise phenotypically normal mice. Consistent with abnormal mechanosignaling, normal cardiac size and function were restored in MFS mice treated with an AT1R antagonist and in MFS mice lacking AT1R or β-arrestin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angiotensinogen. Conversely, DCM associated with abnormal AT1R and FAK signaling was the sole abnormality in mice that were haploinsufficient for both fibrillin 1 and β1 integrin. Collectively, these findings implicate fibrillin 1 in the physiological adaptation of cardiac muscle to elevated workload.

[1]  Patrick Segers,et al.  Primary impairment of left ventricular function in Marfan syndrome. , 2006, International journal of cardiology.

[2]  P. Robinson,et al.  Tissue Doppler imaging identifies myocardial dysfunction in adults with marfan syndrome , 2007, Clinical Cardiology.

[3]  A. Zwinderman,et al.  Intrinsic biventricular dysfunction in Marfan syndrome , 2011, Heart.

[4]  L. Sakai,et al.  Biogenesis and function of fibrillin assemblies , 2009, Cell and Tissue Research.

[5]  H. S. Kim,et al.  Genetic control of blood pressure and the angiotensinogen locus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Colan,et al.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.

[7]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[8]  K. Eagle Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC). , 2009, American heart journal.

[9]  F. Ramirez,et al.  Generation of Fbn1 conditional null mice implicates the extracellular microfibrils in osteoprogenitor recruitment , 2012, Genesis.

[10]  H. Dietz,et al.  p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice* , 2009, Journal of Biological Chemistry.

[11]  L. Hunyady,et al.  Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Entman,et al.  Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[13]  T. Doetschman,et al.  TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II , 2002 .

[14]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[15]  L. Tavazzi,et al.  Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations , 2009, Journal of cardiovascular medicine.

[16]  B. McCrindle,et al.  General cardiology: abstractLong-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death?☆ , 2003 .

[17]  Samarjit Patnaik,et al.  Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice , 2011, Science.

[18]  Kevin D Costa,et al.  Cross-bridge cycling gives rise to spatiotemporal heterogeneity of dynamic subcellular mechanics in cardiac myocytes probed with atomic force microscopy. , 2010, American journal of physiology. Heart and circulatory physiology.

[19]  J. Coselli,et al.  Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. , 1995, Circulation.

[20]  D. Rifkin,et al.  Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. , 2009, Current opinion in cell biology.

[21]  A. Zwinderman,et al.  Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial , 2010, Trials.

[22]  Pál Pacher,et al.  Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats , 2008, Nature Protocols.

[23]  P. Hekali,et al.  Left ventricular function in children with the Marfan syndrome. , 1994, European heart journal.

[24]  Masashi Takahashi,et al.  Myocardial involvement in the Marfan syndrome. , 1985, Japanese heart journal.

[25]  D. Kass,et al.  Thrombospondin-4 Is Required for Stretch-Mediated Contractility Augmentation in Cardiac Muscle , 2011, Circulation research.

[26]  Joyce Wong,et al.  Evidence for Marfan cardiomyopathy , 2010, European journal of heart failure.

[27]  K. Vranizan,et al.  Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Stockman,et al.  Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice , 2012 .

[29]  Henk A Marquering,et al.  Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. , 2013, European heart journal.

[30]  John Camm,et al.  Early impairment of left ventricular long-axis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome. , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[31]  J. Molkentin,et al.  Signaling effectors underlying pathologic growth and remodeling of the heart. , 2013, The Journal of clinical investigation.

[32]  H. Dietz,et al.  Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Geva,et al.  Two-dimensional and Doppler echocardiographic and pathologic characteristics of the infantile Marfan syndrome. , 1990, The American journal of cardiology.

[34]  P. Robinson,et al.  Novel exon skipping mutation in the fibrillin‐1 gene: Two ‘hot spots’ for the neonatal Marfan syndrome , 1999, Clinical genetics.

[35]  B. Das,et al.  Left Ventricular Diastolic Dysfunction in Children and Young Adults with Marfan Syndrome , 2006, Pediatric Cardiology.

[36]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[37]  J. Lincoln,et al.  Reduced Sox9 Function Promotes Heart Valve Calcification Phenotypes In Vivo , 2010, Circulation research.

[38]  Y C Fung,et al.  Residual strain in rat left ventricle. , 1990, Circulation research.

[39]  K. Rakesh,et al.  β-Arrestin–Biased Agonism of the Angiotensin Receptor Induced by Mechanical Stress , 2010, Science Signaling.

[40]  A. Erkol,et al.  Dilated cardiomyopathy in a patient with Marfan syndrome accompanied by chronic type A aortic dissection and right atrial thrombus. , 2010, Internal medicine.

[41]  A. McMahon,et al.  Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. , 2000, Development.

[42]  Jessica Geubtner,et al.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.

[43]  D. Ingber,et al.  Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.

[44]  C. Pham,et al.  Modulation of integrins and integrin signaling molecules in the pressure-loaded murine ventricle , 2002, Histochemistry and Cell Biology.

[45]  R. Pyeritz The Marfan syndrome. , 1986, American family physician.

[46]  N. Koitabashi,et al.  Increased Connective Tissue Growth Factor Relative to Brain Natriuretic Peptide as a Determinant of Myocardial Fibrosis , 2007, Hypertension.

[47]  L. Leinwand,et al.  The cell biology of disease Cellular mechanisms of cardiomyopathy , 2022 .

[48]  I. Komuro,et al.  Conformational switch of angiotensin II type 1 receptor underlying mechanical stress‐induced activation , 2008, EMBO reports.

[49]  D. Keene,et al.  Fibrillins 1 and 2 Perform Partially Overlapping Functions during Aortic Development* , 2006, Journal of Biological Chemistry.

[50]  D. Driscoll,et al.  Left ventricular function in the Marfan syndrome without significant valvular regurgitation. , 2003, American Journal of Cardiology.

[51]  John A Pearce,et al.  Dynamic correction for parallel conductance, GP, and gain factor, alpha, in invasive murine left ventricular volume measurements. , 2009, Journal of applied physiology.

[52]  D. Judge,et al.  Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism , 2011, Science.

[53]  L. Leinwand,et al.  Cellular mechanisms of cardiomyopathy , 2011, The Journal of cell biology.

[54]  J. Timmermans,et al.  Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation. , 2005, The American journal of cardiology.

[55]  W. Pu,et al.  Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. , 2006, Journal of cardiac failure.

[56]  R. Behringer,et al.  Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. M. Foster,et al.  Integrins and proximal signaling mechanisms in cardiovascular disease. , 2009, Frontiers in bioscience.

[58]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[59]  S. Sheehy,et al.  The contribution of cellular mechanotransduction to cardiomyocyte form and function , 2012, Biomechanics and Modeling in Mechanobiology.

[60]  F. Tubach,et al.  Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. , 2010, Archives of cardiovascular diseases.

[61]  Peter D Yurchenco,et al.  Laminin assembles into separate basement membrane and fibrillar matrices in Schwann cells. , 2002, Journal of cell science.